Case Study
JPM 2026 Signal: AI Is Moving from Talk to Transactions & CMS priorities around Drug-to-Drug interaction and patient safety
The biopharma dealmaking landscape is poised for a decisive acceleration in 2026, driven by aconvergence of capital returning to the sector, increased urgency around pipelinediversification, and a maturing cohort of AI-enabled drug discovery platforms that are finallyproducing clinically validated assets.
Fill out the form to download the slide deck.
Thank you. We'll be in touch shortly.
Oops! Something went wrong while submitting the form.